Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression

Biomedicine and Pharmacotherapy

Volumn 63, Issue 5, 2009, Pages 375-379

  Guo, Renhua ^a   Huang, Zuhu ^a   Shu, Yongqian ^a   Jin, Shidai ^a   Ge, Hongmei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Estrogen receptor; Survivin

Indexed keywords

ESTROGEN RECEPTOR; SURVIVIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; TAMOXIFEN;

EID: 68649084732     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.09.010     Document Type: Article

References (34)

1. Gelmann E. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24 (1997) 165-170
2. Elba S., Giannuzzi V., Misciagna G., and Manghisi O.G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 26 (1994) 66-68
3. Martinez Cerezo F.J., Tomas A., Donoso L., Enriquez J., Guarner C., Balanzo J., et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 20 (1994) 702-706
4. Boix L., Bruix J., Castells A., Fuster J., Bru C., Visa J., et al. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment?. J Hepatol 17 (1993) 187-191
5. Villa E., Camellini L., Dugani A., Zucchi F., Grottola A., Merighi A., et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 55 (1995) 498-500
6. Villa E., Camellini L., Dugani A., Buttafoco P., Grottola A., and Manenti F. Variant liver estrogen receptors and response to tamoxifen. [letter]. Gastroenterology 111 (1996) 271-272
7. Mandlekar S., and Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
8. 2+ influx in the mechanism of tamoxifen-induced apoptosis in HepG2 human hepatoblastoma cells. Cancer Lett 147 (1999) 115-123
9. Lee Y.S., Kang Y.S., and Lee S.H. Role of NADPH oxidase in tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 7 (2000) 925-932
10. Cheng A.L., Chuang S.E., Fine R.L., Yeh K.H., Liao C.M., Lay J.D., et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 55 (1998) 523-531
11. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas [CD95], Bax, caspases, and anticancer drugs. Cancer Res 58 (1998) 5315-5320
12. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
13. Ambrosini G., Adida C., Sirugo G., and Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273 (1998) 11177-11182
14. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., et al. A novel anti-apoptosis gene: reexpression of survivin messenger RNA as a prognosis marker in non small cell lung cancers. J Clin Oncol 17 (1999) 2100-2104
15. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
16. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 11 (1998) 115-124
17. Zaffaroni N., and Daidone M.G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5 (2002) 65-72
18. Asanuma K., Moriai R., Yajima T., Yagihashi A., Yamada M., Kobayashi D., et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91 (2000) 1204-1209
19. Olie R.A., Simoes-Wust A.P., Baumann B., Leech S.H., Fabbro D., Stahel R.A., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
20. Carvalho A., Carmena M., Sambade C., Earnshaw W.C., and Wheatley S.P. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116 (2003) 2987-2998
21. Daly C., Wong V., Burova E., Wei Y., Zabski S., Griffiths J., et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR [FOXO1]. Genes Dev 18 (2004) 1060-1071
22. Ling X., Bernacki R.J., Brattain M.G., and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279 (2004) 15196-15203
23. Song H., Xin X.Y., Xiao F., Wang D.T., Yue Q.H., and Han X. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol 136 (2008) 83-89
24. Ma X., Wang S., Zhou J., Xing H., Xu G., Wang B., et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep 14 (2005) 275-279
25. Cheng S.Q., Wang W.L., Yan W., Li Q.L., Wang L., and Wang W.Y. Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721. World J Gastroenterol 11 (2005) 756-759
26. Gundimeda U., Chen Z.H., and Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271 (1996) 13504-13514
27. Xiao D., Wang K., Zhou J., Cao H., Deng Z., Hu Y., et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells. Acta Biochim Biophys Sin 40 (2008) 297-303
28. Szlávik V., Vág J., Markó K., Demeter K., Madarász E., Oláh I., et al. Matrigel-induced acinar differentiation is followed by apoptosis in HSG cells. J Cell Biochem 103 (2008) 284-295
29. Jiang S.Y., Shyu R.Y., Yeh M.Y., and Jordan V.C. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 23 (1995) 712-719
30. Tan C.K., Chow P.K., Findlay M., Wong C., and Machin D. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol Hepatol 15 (2000) 725-729
31. Taylor C.M., Blanchard B., and Zava D.T. Estrogen receptormediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44 (1984) 1409-1414
32. Lien E.A., Sohlheim E., and Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51 (1991) 4837-4844
33. Johnston S.R. Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 8 (1997) 911-930
34. Farinati F. Tamoxifen treatment in hepatocellular carcinoma. Gastroenterology 111 (1996) 272-274